ABSTRACT
COVID-19 is a newly emerged disease that has become a global public health challenge. Due to a lack of knowledge about the virus, a significant number of potential targets for using a particular drug have been proposed. Five cases with a clinical history of biopolymers in the gluteal region that developed iatrogenic allogenosis (IA) are presented here. The 5 cases were put under colchicine treatment for IA crisis and had non-specific symptoms (headache, cough without dyspnea, and arthralgias) with a positive SARS-CoV-2 test. Their close contacts had mild to severe symptoms and three of them died. In the SARS-CoV-2 infection different inflammatory pathways are altered where colchicine reduces cytokine levels as well as the activation of macrophages, neutrophils, and the inflammasome. The possible mechanisms that colchicine may use to prevent acute respiratory distress syndrome (ARDS) in patients with COVID-19 infection are also reviewed in this article.(AU)
COVID-19 es una enfermedad de aparición reciente, que se ha convertido en un reto global de salud pública. Debido a la falta de conocimiento acerca del virus, se ha propuesto un número significativo de objetivos potenciales para utilizar un fármaco en particular. Presentamos 5 casos con historia clínica de biopolímeros en la región glútea, que desarrollaron alogenosis iatrogénica (AI). A los 5 casos se les administró tratamiento de colchicina debido a la crisis de AI, no teniendo síntomas específicos (cefalea, tos sin disnea y artralgias), con resultado positivo en el test de SARS-CoV-2. Sus contactos cercanos tenían síntomas de leves a graves, y 3 de ellos fallecieron. En la infección por SARS-CoV-2 se alteran diferentes rutas inflamatorias, en las que la colchicina reduce los niveles de citocinas y la activación de macrófagos, neutrófilos e inflamasoma. Revisamos también, en este artículo, los posibles mecanismos que puede utilizar colchicina para prevenir el síndrome de distrés respiratorio agudo (SDRA) en pacientes con COVID-19.(AU)
Subject(s)
Humans , Male , Female , Middle Aged , Colchicine , Severe acute respiratory syndrome-related coronavirus , Pandemics , Coronavirus Infections , Patients , Inflammasomes , Severe Acute Respiratory SyndromeABSTRACT
COVID-19 is a newly emerged disease that has become a global public health challenge. Due to a lack of knowledge about the virus, a significant number of potential targets for using a particular drug have been proposed. Five cases with a clinical history of biopolymers in the gluteal region that developed iatrogenic allogenosis (IA) are presented here. The 5 cases were put under colchicine treatment for IA crisis and had non-specific symptoms (headache, cough without dyspnea, and arthralgias) with a positive SARS-CoV-2 test. Their close contacts had mild to severe symptoms and three of them died. In the SARS-CoV-2 infection different inflammatory pathways are altered where colchicine reduces cytokine levels as well as the activation of macrophages, neutrophils, and the inflammasome. The possible mechanisms that colchicine may use to prevent acute respiratory distress syndrome (ARDS) in patients with COVID-19 infection are also reviewed in this article.
Subject(s)
Anti-Inflammatory Agents/therapeutic use , COVID-19 Drug Treatment , Colchicine/therapeutic use , Respiratory Distress Syndrome/prevention & control , Tubulin Modulators/therapeutic use , Adult , COVID-19/complications , COVID-19/diagnosis , Female , Humans , Middle Aged , Respiratory Distress Syndrome/virology , Severity of Illness IndexABSTRACT
COVID-19 is a newly emerged disease that has become a global public health challenge. Due to a lack of knowledge about the virus, a significant number of potential targets for using a particular drug have been proposed. Five cases with a clinical history of biopolymers in the gluteal region that developed iatrogenic allogenosis (IA) are presented here. The 5 cases were put under colchicine treatment for IA crisis and had non-specific symptoms (headache, cough without dyspnea, and arthralgias) with a positive SARS-CoV-2 test. Their close contacts had mild to severe symptoms and three of them died. In the SARS-CoV-2 infection different inflammatory pathways are altered where colchicine reduces cytokine levels as well as the activation of macrophages, neutrophils, and the inflammasome. The possible mechanisms that colchicine may use to prevent acute respiratory distress syndrome (ARDS) in patients with COVID-19 infection are also reviewed in this article.
COVID-19 es una enfermedad de aparición reciente, que se ha convertido en un reto global de salud pública. Debido a la falta de conocimiento acerca del virus, se ha propuesto un número significativo de objetivos potenciales para utilizar un fármaco en particular. Presentamos 5 casos con historia clínica de biopolímeros en la región glútea, que desarrollaron alogenosis iatrogénica (AI). A los 5 casos se les administró tratamiento de colchicina debido a la crisis de AI, no teniendo síntomas específicos (cefalea, tos sin disnea y artralgias), con resultado positivo en el test de SARS-CoV-2. Sus contactos cercanos tenían síntomas de leves a graves, y 3 de ellos fallecieron. En la infección por SARS-CoV-2 se alteran diferentes rutas inflamatorias, en las que la colchicina reduce los niveles de citocinas y la activación de macrófagos, neutrófilos e inflamasoma. Revisamos también, en este artículo, los posibles mecanismos que puede utilizar colchicina para prevenir el síndrome de distrés respiratorio agudo (SDRA) en pacientes con COVID-19.
Subject(s)
Betacoronavirus , Coronavirus Infections , Pandemics , Pneumonia, Viral , COVID-19 , Colchicine , Humans , SARS-CoV-2ABSTRACT
COVID-19 is a newly emerged disease that has become a global public health challenge. Due to a lack of knowledge about the virus, a significant number of potential targets for using a particular drug have been proposed. Five cases with a clinical history of biopolymers in the gluteal region that developed iatrogenic allogenosis (IA) are presented here. The 5 cases were put under colchicine treatment for IA crisis and had non-specific symptoms (headache, cough without dyspnoea, and arthralgias) with a positive SARS-CoV-2 test. Their close contacts had mild to severe symptoms and three of them died. In the SARS-CoV-2 infection different inflammatory pathways are altered where colchicine reduces cytokine levels as well as the activation of macrophages, neutrophils, and the inflammasome. The possible mechanisms that colchicine may use to prevent acute respiratory distress syndrome (ARDS) in patients with COVID-19 infection are also reviewed in this article
COVID-19 es una enfermedad de aparición reciente, que se ha convertido en un reto global de salud pública. Debido a la falta de conocimiento acerca del virus, se ha propuesto un número significativo de objetivos potenciales para utilizar un fármaco en particular. Presentamos aquí cinco casos con historia clínica de biopolímeros en la región glútea, que desarrollaron alogenosis iatrogénica (AI). A los 5 casos se les administró tratamiento de colchicina debido a crisis de AI, no teniendo síntomas específicos (cefalea, tos sin disnea, y artralgias), con resultado positivo en el test de SARS-CoV-2. Sus contactos cercanos tenían síntomas de leves a graves, y tres de ellos fallecieron. En la infección por SARS-CoV-2 se alteran diferentes rutas inflamatorias, en las que la colchicina reduce los niveles de citocinas y la activación de macrófagos, neutrófilos e inflamasoma. Revisamos también en este artículo los posibles mecanismos que puede utilizar colchicina para prevenir el síndrome de distrés respiratorio agudo (SDRA) en pacientes con COVID-19
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Colchicine/pharmacokinetics , Coronavirus Infections/drug therapy , Severe Acute Respiratory Syndrome/drug therapy , Severe acute respiratory syndrome-related coronavirus/pathogenicity , Inflammasomes/analysis , Virus Replication/immunology , Colchicine/metabolismABSTRACT
No disponible
Subject(s)
Humans , Myocutaneous Flap/trends , Cervical Vertebrae/abnormalities , Cervical Vertebrae/surgery , Musculocutaneous Nerve/abnormalities , Musculocutaneous Nerve/surgerySubject(s)
Body Contouring/adverse effects , Fasciitis, Necrotizing/etiology , Lymphoma, Large B-Cell, Diffuse/pathology , Prosthesis-Related Infections/etiology , Silicone Gels/adverse effects , Biopolymers/adverse effects , Body Contouring/methods , Buttocks/surgery , Fasciitis, Necrotizing/surgery , Female , Humans , Lymph Nodes/pathology , Lymphoma, Large B-Cell, Diffuse/etiology , Middle Aged , Prostheses and Implants/adverse effects , Prosthesis-Related Infections/surgery , ThighABSTRACT
El ganglión es la nodulación benigna del tejido blando más frecuente en la mano y el puño. Se origina de la cápsula articular y en las vainas tendinosas. Su presentación más frecuente es en el dorso del punË o, pero puede provenir de cualquier articulación de la mano. Su diagnóstico requiere de la evaluación clínica y el estudio imagenológico. En este reporte se muestra un caso donde el diagnóstico clínico, imagenológico e intraoperatorio fue «ganglión¼ de la articulación radio cubital distal, cuyo estudio histopatológico reportó un cistadenoma apocrino.
The ganglion cyst is the most common type of soft tissue benign mass that occurs in the hand and wrist. Gangliamay result fromany joint capsule or tendon sheath. They most often occur at the dorsum of the wrist, but they may arise from any joint of the hand. Ganglion cysts require a clinical and diagnostic imaging assessment to be diagnosed. In this case, the clinical, imaging tests and macroscopic surgical diagnosis was a "ganglion cyst" of the distal radioulnar joint, however, histopathology led to diagnosis of an apocrine cystadenoma.
